Table 1 Rituximab in non-Hodgkin's lymphoma pivotal trial: infections
From: B cell non-Hodgkin's lymphoma: rituximab safety experience
Patients monitored throughout treatment and >1 year follow up |
Despite B cell depletion, incidence of infection was not increased |
Most infections were typical of those common in normal hosts |
Predominantly bacterial |
Seven episodes of grade 3 infections |
No patients experienced grade 4 infections |